|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kishiki T, Lapin B, Matsuoka H, Watanabe
T, Takayasu K, Kojima K, Sugihara K and Masaki T: Optimal
surveillance protocols after curative resection in patients with
stage IV colorectal cancer: A multicenter retrospective study. Dis
Colon Rectum. 61:51–57. 2018.
|
|
3
|
van der Stok EP, Spaander MCW, Grünhagen
DJ, Verhoef C and Kuipers EJ: Surveillance after curative treatment
for colorectal cancer. Nat Rev Clin Oncol. 14:297–315. 2017.
View Article : Google Scholar
|
|
4
|
Kahi CJ, Boland CR, Dominitz JA,
Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR,
Robertson DJ and Rex DK; United States Multi-Society Task Force on
Colorectal Cancer: Colonoscopy surveillance after colorectal cancer
resection: Recommendations of the US Multi-society task force on
colorectal cancer. Gastroenterology. 150:758–768.e11. 2016.
View Article : Google Scholar
|
|
5
|
Cooper JA, Parsons N, Stinton C, Mathews
C, Smith S, Halloran SP, Moss S and Taylor-Phillips S:
Risk-adjusted colorectal cancer screening using the FIT and routine
screening data: Development of a risk prediction model. Br J
Cancer. 118:285–293. 2018. View Article : Google Scholar :
|
|
6
|
Westwood M, Lang S, Armstrong N, van
Turenhout S, Cubiella J, Stirk L, Ramos IC, Luyendijk M, Zaim R,
Kleijnen J and Fraser CG: Faecal immunochemical tests (FIT) can
help to rule out colorectal cancer in patients presenting in
primary care with lower abdominal symptoms: A systematic review
conducted to inform new NICE DG30 diagnostic guidance. BMC Med.
15:1892017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Passamonti B, Malaspina M, Fraser CG,
Tintori B, Carlani A, D'Angelo V, Galeazzi P, Di Dato E, Mariotti
L, Bulletti S, et al: A comparative effectiveness trial of two
faecal immunochemical tests for haemoglobin (FIT). Assessment of
test performance and adherence in a single round of a
population-based screening programme for colorectal cancer. Gut.
67:485–496. 2018. View Article : Google Scholar
|
|
8
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
11
|
van Geel RM, Beijnen JH, Bernards R and
Schellens JH: Treatment individualization in colorectal cancer.
Curr Colorectal Cancer Rep. 11:335–344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakurai T, Kashida H, Watanabe T, Hagiwara
S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J and
Kudo M: Stress response protein cirp links inflammation and
tumorigenesis in colitis-associated cancer. Cancer Res.
74:6119–6128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Waldner MJ and Neurath MF: Master
regulator of intestinal disease: IL-6 in chronic inflammation and
cancer development. Semin Immunol. 26:75–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Cao AT and Cong Y: Microbiota
regulation of inflammatory bowel disease and colorectal cancer.
Semin Cancer Biol. 23:543–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cho YA, Lee J, Oh JH, Chang HJ, Sohn DK,
Shin A and Kim J: Genetic variation in PARGC1A may affect the role
of diet-associated inflammation in colorectal carcinogenesis.
Oncotarget. 8:8550–8558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Zhou Z, Zhang X, Zheng L, He D, Ye
Y, Zhang QQ, Qi CL, He XD, Yu C, et al: Inflammatory molecule,
PSGL-1, deficiency activates macrophages to promote colorectal
cancer growth through NFκB signaling. Mol Cancer Res. 15:467–477.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chuang HY, Lee E, Liu YT, Lee D and Ideker
T: Network-based classification of breast cancer metastasis. Mol
Syst Biol. 3:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J, Lenferink AE, Deng Y, Collins C, Cui
Q, Purisima EO, O'Connor-McCourt MD and Wang E: Identification of
high-quality cancer prognostic markers and metastasis network
modules. Nat Commun. 1:342010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sveen A, Agesen TH, Nesbakken A, Rognum
TO, Lothe RA and Skotheim RI: Transcriptome instability in
colorectal cancer identified by exon microarray analyses:
Associations with splicing factor expression levels and patient
survival. Genome Med. 3:322011. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sveen A, Ågesen TH, Nesbakken A, Meling
GI, Rognum TO, Liestøl K, Skotheim RI and Lothe RA: ColoGuidePro: A
prognostic 7-gene expression signature for stage III colorectal
cancer patients. Clin Cancer Res. 18:6001–6010. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Agesen TH, Sveen A, Merok MA, Lind GE,
Nesbakken A, Skotheim RI and Lothe RA: ColoGuideEx: A robust gene
classifier specific for stage II colorectal cancer prognosis. Gut.
61:1560–1567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Plaisier CL, Pan M and Baliga NS: A
miRNA-regulatory network explains how dysregulated miRNAs perturb
oncogenic processes across diverse cancers. Genome Res.
22:2302–2314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carbon S, Ireland A, Mungall CJ, Shu S,
Marshall B and Lewis S; AmiGO Hub; Web Presence Working Group:
AmiGO: Online access to ontology and annotation data.
Bioinformatics. 25:288–289. 2009. View Article : Google Scholar :
|
|
27
|
Peri S, Navarro JD, Kristiansen TZ,
Amanchy R, Surendranath V, Muthusamy B, Gandhi TK, Chandrika KN,
Deshpande N, Suresh S, et al: Human protein reference database as a
discovery resource for proteomics. Nucleic Acids Res. 32:D497–D501.
2004. View Article : Google Scholar :
|
|
28
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheadle C, Vawter MP, Freed WJ and Becker
KG: Analysis of microarray data using Z score transformation. J Mol
Diagn. 5:73–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang C, Jiang W, Li W, Lian B, Chen X, Hua
L, Lin H, Li D, Li X and Liu Z: Topological properties of the drug
targets regulated by microRNA in human protein-protein interaction
network. J Drug Target. 19:354–364. 2011. View Article : Google Scholar
|
|
32
|
Adamcsek B, Palla G, Farkas IJ, Derényi I
and Vicsek T: CFinder: Locating cliques and overlapping modules in
biological networks. Bioinformatics. 22:1021–1023. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Palla G, Derényi I, Farkas I and Vicsek T:
Uncovering the overlapping community structure of complex networks
in nature and society. Nature. 435:814–818. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar
|
|
35
|
Merico D, Isserlin R, Stueker O, Emili A
and Bader GD: Enrichment map: A network-based method for gene-set
enrichment visualization and interpretation. PLoS One.
5:e139842010. View Article : Google Scholar :
|
|
36
|
Alizadeh AA, Gentles AJ, Alencar AJ, Liu
CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH,
et al: Prediction of survival in diffuse large B-cell lymphoma
based on the expression of 2 genes reflecting tumor and
microenvironment. Blood. 118:1350–1358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z,
Shao T, Zhang J, Wang L and Li X: The mRNA related ceRNA-ceRNA
landscape and significance across 20 major cancer types. Nucleic
Acids Res. 43:8169–8182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu SL, Chen HY, Chang GC, Chen CY, Chen
HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al: MicroRNA
signature predicts survival and relapse in lung cancer. Cancer
Cell. 13:48–57. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Attoub S, Rivat C, Rodrigues S, Van
Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T,
Mareel M, et al: The c-kit tyrosine kinase inhibitor STI571 for
colorectal cancer therapy. Cancer Res. 62:4879–4883.
2002.PubMed/NCBI
|
|
40
|
Montero JC, Seoane S, Ocaña A and
Pandiella A: Inhibition of SRC family kinases and receptor tyrosine
kinases by dasatinib: Possible combinations in solid tumors. Clin
Cancer Res. 17:5546–5552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Blaj C, Schmidt EM, Lamprecht S, Hermeking
H, Jung A, Kirchner T and Horst D: Oncogenic effects of high MAPK
activity in colorectal cancer mark progenitor cells and persist
irrespective of RAS mutations. Cancer Res. 77:1763–1774. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barry GS, Cheang MC, Chang HL and Kennecke
HF: Genomic markers of panitumumab resistance including ERBB2/HER2
in a phase II study of KRAS wild-type (wt) metastatic colorectal
cancer (mCRC). Oncotarget. 7:18953–18964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang SW, Hu J, Guo QH, Zhao Y, Cheng JJ,
Zhang DS, Fei Q, Li J and Sun YM: AZD1480, a JAK inhibitor,
inhibits cell growth and survival of colorectal cancer via
modulating the JAK2/STAT3 signaling pathway. Oncol Rep.
32:1991–1998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xiong H, Du W, Zhang YJ, Hong J, Su WY,
Tang JT, Wang YC, Lu R and Fang JY: Trichostatin A, a histone
deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing
the promoter-associated histone acetylation of SOCS1 and SOCS3 in
human colorectal cancer cells. Mol Carcinog. 51:174–184. 2012.
View Article : Google Scholar
|
|
45
|
Hickish T, Andre T, Wyrwicz L, Saunders M,
Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K,
Petruzelka L, et al: MABp1 as a novel antibody treatment for
advanced colorectal cancer: A randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 18:192–201. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Foersch S, Sperka T, Lindner C, Taut A,
Rudolph KL, Breier G, Boxberger F, Rau TT, Hartmann A, Stürzl M, et
al: VEGFR2 signaling prevents colorectal cancer cell senescence to
promote tumorigenesis in mice with colitis. Gastroenterology.
149:177–189.e10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu Q, Man SM, Gurung P, Liu Z, Vogel P,
Lamkanfi M and Kanneganti TD: Cutting edge: STING mediates
protection against colorectal tumorigenesis by governing the
magnitude of intestinal inflammation. J Immunol. 193:4779–4782.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim MS and Lee SH, Yoo NJ and Lee SH:
Frameshift mutations of tumor suppressor gene EP300 in gastric and
colorectal cancers with high microsatellite instability. Hum
Pathol. 44:2064–2070. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sirvent A, Benistant C and Roche S:
Oncogenic signaling by tyrosine kinases of the SRC family in
advanced colorectal cancer. Am J Cancer Res. 2:357–371.
2012.PubMed/NCBI
|
|
50
|
Bordonaro M and Lazarova DL: CREB-binding
protein, p300 butyrate, and Wnt signaling in colorectal cancer.
World J Gastroenterol. 21:8238–8248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ding C, Luo J, Yu W, Gao S, Yang L, Chen C
and Feng J: Gab2 is a novel prognostic factor for colorectal cancer
patients. Int J Clin Exp Pathol. 8:2779–2786. 2015.PubMed/NCBI
|
|
52
|
Lowenberg M, Verhaar A, van den Blink B,
Ten Kate F, van Deventer S, Peppelenbosch M and Hommes D: Specific
inhibition of c-Raf activity by semapimod induces clinical
remission in severe Crohn's disease. J Immunol. 175:2293–2300.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hardwick JC, van den Brink GR, Offerhaus
GJ, van Deventer SJ and Peppelenbosch MP: NF-kappaB, p38 MAPK and
JNK are highly expressed and active in the stroma of human colonic
adenomatous polyps. Oncogene. 20:819–827. 2001. View Article : Google Scholar : PubMed/NCBI
|
